News
RXST
54.92
+4.93%
2.58
RxSight, Inc. to Report First Quarter Financial Results on May 6, 2024
RxSight, Inc. Will report financial results for the first quarter of 2024 after the market close on May 6, 2024. The company's management will discuss the results during a conference call. RxSight is an ophthalmic medical device company dedicated to providing customized vision to patients following cataract surgery.
Barchart · 1d ago
Weekly Report: what happened at RXST last week (0415-0419)?
Weekly Report · 1d ago
Weekly Report: what happened at RXST last week (0408-0412)?
Weekly Report · 04/15 11:46
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
Needham sees BSX, CNMD, RMD and Surmodics beating Street, despite medtech slow down. Needham estimates medtech sales grew less than expected in Q1, but that Boston Scientific, CONMED and ResMed should still beat the Street. The investment firm says medtech market only grew by 5.3% in the first quarter of 2024.
Seeking Alpha · 04/14 21:56
Assessing RxSight: Insights From 8 Financial Analysts
RxSight (NASDAQ:RXST) underwent analysis by 8 analysts in the last quarter. The company offers intraocular lens technology to improve the vision of patients following cataract surgery. RxSight has an average 12-month price target of $59.12 and a high estimate of $64.00. The company is a commercial-stage medical technology company.
Benzinga · 04/11 12:00
Analysts Have Conflicting Sentiments on These Healthcare Companies: Abivax SA Sponsored ADR (ABVX), RxSight (RXST) and Clearside Biomedical (CLSD)
TipRanks · 04/11 09:50
Weekly Report: what happened at RXST last week (0401-0405)?
Weekly Report · 04/08 11:52
RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting
RxSight, Inc. Announces the commercial launch of its newest Light Adjustable Lens, the LAL+. The LAL+ has a modified aspheric anterior surface that creates a small continuous increase in central lens power. The company now offers two lenses in the Light adjustable Lens platform.
Barchart · 04/04 15:05
Weekly Report: what happened at RXST last week (0325-0329)?
Weekly Report · 04/01 11:49
RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Barchart · 03/27 15:05
Weekly Report: what happened at RXST last week (0318-0322)?
Weekly Report · 03/25 11:53
Weekly Report: what happened at RXST last week (0311-0315)?
Weekly Report · 03/18 11:51
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
NASDAQ · 03/15 10:20
Weekly Report: what happened at RXST last week (0304-0308)?
Weekly Report · 03/11 11:46
Rxsight, Inc.: Statement of changes in beneficial ownership of securities
Press release · 03/07 04:02
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
NASDAQ · 03/06 11:20
What's in the Offing for Brainsway (BWAY) in Q4 Earnings?
NASDAQ · 03/05 13:20
Patrick Wood Reaffirms Buy Rating for RxSight Amid Strong Growth and Market Expansion Potential
TipRanks · 03/04 19:05
Weekly Report: what happened at RXST last week (0226-0301)?
Weekly Report · 03/04 11:50
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
NASDAQ · 03/04 11:20
More
Webull provides a variety of real-time RXST stock news. You can receive the latest news about Rxsight, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RXST
RxSight, Inc. is a commercial-stage medical technology company, which is engaged in improving the vision of patients following cataract surgery. The Company’s RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patient’s vision outcomes.